The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Nina, Aiello, Jack, Avigan, David E, Berdeja, Jesus G, Borrello, Ivan M, Chari, Ajai, Cohen, Adam D, Ganapathi, Karthik, Gray, Lissa, Green, Damian, Krishnan, Amrita, Lin, Yi, Manasanch, Elisabet, Munshi, Nikhil C, Nooka, Ajay K, Rapoport, Aaron P, Smith, Eric L, Vij, Ravi, Dhodapkar, Madhav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359060/
https://www.ncbi.nlm.nih.gov/pubmed/32661116
http://dx.doi.org/10.1136/jitc-2020-000734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359060/
https://www.ncbi.nlm.nih.gov/pubmed/32661116
http://dx.doi.org/10.1136/jitc-2020-000734

Ejemplares similares